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support for individual patients, accurate statistical models to predict locoregional
relapse (LRR), distant relapse (DR), overall survival (OS), and disease-free survival
(DFS) are required.
Methods and Materials: Clinical trial data from the randomized Post Operative Ra-
diation Therapy for Endometrial Cancer (PORTEC-1; NZ714 patients) and
PORTEC-2 (NZ427 patients) trials and registered group (grade 3 and deep invasion,
nZ99) were pooled for analysis (NZ1240). For most patients (86%) pathology re-
view data were available; otherwise original pathology data were used. Trial variables
which were clinically relevant and eligible according to data constraints were age,
stage, given treatment (pelvic external beam radiation therapy (EBRT), vaginal
brachytherapy (VBT), or no adjuvant treatment, FIGO histological grade, depth of in-
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able for patient counseling
and shared decision making,
especially as they include the
effect of external beam radi-
ation therapy or vaginal
brachytherapy on the risks of
locoregional relapse and
disease-free survival.Cox proportional hazards regression model. Predictors were selected based on a back-
ward elimination scheme. Model results were expressed by the c-index (0.5-1.0;
random to perfect prediction). Two validation sets (nZ244 and 291 patients) were
used.
Results: Accuracy of the developed models was good, with training accuracies be-
tween 0.71 and 0.78. The nomograms validated well for DR (0.73), DFS (0.69),
and OS (0.70), but validation was only fair for LRR (0.59). Ranking of variables
as to their predictive power showed that age, tumor grade, and LVSI were highly pre-
dictive for all outcomes, and given treatment for LRR and DFS. The nomograms were
able to significantly distinguish low- from high-probability patients for these out-
comes.
Conclusions: The nomograms are internally validated and able to accurately predict
long-term outcome for endometrial cancer patients with observation, pelvic EBRT, or
VBT after surgery. These models facilitate decision support in daily clinical practice
and can be used for patient counseling and shared decision making, selecting patients
who benefit most from adjuvant treatment, and generating new hypotheses.
 2015 Elsevier Inc.Introduction
Endometrial cancer (EC) is the most common gynecolog-
ical cancer in developed countries. Surgery is the corner-
stone of treatment. Postoperative pelvic external beam
radiation therapy (EBRT) for early stage EC has been
shown in multiple randomized trials to significantly in-
crease locoregional control but has no impact on overall
survival (OS) (1, 2). The indication for adjuvant RT is
tailored to the risk of recurrence. This spares most EC
patients with a favorable prognosis the negative effects of
pelvic EBRT, and significantly reduces the risk of disease
recurrence, with its associated anxiety and stress, and the
toxicities of salvage treatment in the minority of patients
who are at higher risk (3). Using pelvic EBRT for patients
with low-risk disease may even negatively affect their
eventual outcome (2, 4).
For EC patients with high-intermediate risk factors,
vaginal brachytherapy (VBT) alone has been shown to
result in excellent vaginal cancer control, without the short-
and long-term toxicities of EBRT (5, 6). To refine the
indication for adjuvant therapy among patients with risk
factors and to identify the occasional patient with higher
risk among those with a low-risk profile, studies of mo-
lecular genetic risk factors are increasingly being done, and
some have shown promising results (7, 8).
When patients are asked about their treatment prefer-
ences, in most cases they favor adjuvant treatment to
ensure they have used all possible treatments to reduce the
risk of cancer recurrence. In addition, they do wish to be
involved in clinical decision making and be informed
about the risk and benefits of alternative treatment options,
and make an informed, joint decision together with their
physician (9, 10).
Recently, treatment decision support nomograms have
been developed by several groups to facilitate patientinformation and counseling based on their individual situ-
ation and individual risks of local, regional, and distant
recurrence. Such systems have been based on large data-
bases of historical patients and have incorporated various
patient and tumor characteristics and outcomes (11-13).
The Australian nomogram, which is also available as a
mobile phone application, has been based on results of
2097 patients and is focused on assessing the individual
patient’s risk of isolated locoregional and distant recurrence
(12). The Memorial Sloan-Kettering Cancer Center
nomogram informs on the risk of 3-year OS, without
differentiating between local and distant relapse (DR) (11).
The most recent nomogram, developed by AlHilli et al
(13), is focused on assessing the individual patient’s risk of
(microscopic) pelvic lymph node metastases, to be used for
patient counseling regarding the indication for second
surgery; they used clinical data from 883 patients treated
over a 10-year time period.
None of the previous studies has been able to include
adjuvant treatment modalities in the risk prediction models,
as adjuvant treatment had not been used consistently over
the long study periods. This would require a patient cohort
in which adjuvant treatment was used consistently and
preferably randomly allocated. For most patients with early
stage disease, the inclusion of outcomes with or without
adjuvant RT, specifically pelvic EBRT and VBT, would be
highly desirable to facilitate individual patient counseling
on the risks and benefits of using adjuvant treatment in their
particular situation.
We combined the databases from the randomized Post
Operative Radiation Therapy for Endometrial Cancer
(PORTEC)-1 and PORTEC-2 trials and used this pooled
patient data set, in which adjuvant treatment had been
randomly allocated to develop such treatment decision
support nomograms, including outcomes with and without
adjuvant treatment.
Table 1 Trial and treatment information





















Abbreviations: EBRT Z pelvic external beam radiation therapy;
VBT Z vaginal brachytherapy.
* Registered patients with grade 3 and outer myometrial invasion
were all given EBRT.
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Patient and tumor characteristics
Clinical trial data from the PORTEC-1 (NZ714 patients)
and PORTEC-2 (NZ427 patients) trials and the PORTEC
registration group with grade 3 and deep invasion (NZ99
patients) were pooled for this analysis, providing a total
number of 1240 patients. In the PORTEC-1 trial, patients
with stage I EC with low-intermediate and high-
intermediate risk features were randomly allocated to
adjuvant EBRT and observation after surgery (14, 15) In the
PORTEC-2 trial, patients with stage I EC (and International
Federation of Gynecology and Obstetrics [FIGO] 1988
stage IIA, which are classified as stage I in the 2009 FIGO
staging) with high-intermediate risk factors were randomly
allocated to pelvic EBRT or VBT (5). During the inclusion
period of the PORTEC-1 trial, stage I patients with high-
risk factors (grade 3 with deep myometrial invasion) were
not randomized but were registered, and all received
adjuvant pelvic EBRT (16). Finally, 2 validation sets were
used. The first was obtained from the Maastricht radiation
oncology retrospective database, including all patients who
fitted the inclusion criteria for PORTEC-1 and PORTEC-2
trials and the high-risk registry group (but who were not
included in those trials) and who had been treated between
1978 and 2010 (nZ244 patients). The second validation set
was obtained from the Medisch Spectrum Twente Enschede
endometrial carcinoma database, which included all pa-
tients who fitted the same criteria and had been treated for
FIGO 1988 stages I to IIA between August 1988 and March
2014, with exclusion of those patients who had participated
in one of the PORTEC trials (nZ291 patients).
Patient and tumor characteristics and outcome data were
obtained from the trial databases (Tables 1 and 2) (5, 15).
Data from the pathology review from both trials were used
if available (80% for PORTEC-1 and 90% for PORTEC-2;
overall 86%); otherwise, original pathology data were used.
Age was calculated at the time of randomization. Time-to-
event analyses were done from the date of surgery, as this
date was available for all patients, including the registered
and validation groups. Patients lost to follow-up (nZ42)
were considered censored at the day of last follow-up.
Median follow-up for patients alive was 160 months for
PORTEC-1 and 89 months for PORTEC-2 and 213 and 90
months for the Maastricht and Enschede validation sets,
respectively.
Initially, the following variables were selected as clini-
cally relevant for follow-up outcome: FIGO 1988 (sub)
stage, age, FIGO grade, depth of myometrial invasion,
width of the uninvolved myometrium, distance between the
point of deepest tumor invasion to the serosal surface,
lymph-vascular space invasion and/or angioinvasion,
involvement of the cornuae (uterine cornua or horns), and
treatment given. Variables that were not used because the
percentage of missing values was too high or variationpower of values was too low included FIGO 1988 (sub)
stage (deterministic with myometrial invasion and grade),
width of the uninvolved myometrium, and distance from
the serosa (too many missing values). Peritoneal cytology
was not taken into account because of the rarity of malig-
nant findings.
Clinical, pathologic, and treatment variables were tested
for significance. The variables that were used in the final
analysis were age (as continuous variable), treatment given
(pelvic EBRT, VBT, or no adjuvant treatment), FIGO his-
tological grade, depth of myometrial invasion, involvement
of the cornuae uteri (where the myometrium is thinnest),
and lymph-vascular space invasion (LVSI) and/or angioin-
vasion. Outcome data were defined as vaginal relapse (VR),
pelvic relapse (PR), combined locoregional relapse (LRR
[vaginal and/or pelvic]), DR, OS, and disease-free survival
(DFS).
OS was taken from date of randomization or surgery (for
nontrial patients) with failure defined as death regardless of
the cause and censored at the date of last contact for pa-
tients still alive; for DFS, with failure taken as death or
relapse, whichever occurred first, and censored at the date
of last contact for patients still alive and disease free.
Statistical methods
Any missing values were imputed by the expectation-
maximization algorithm. Data were normalized (mean, 0;
standard deviation, 1) before any analysis was performed.
Table 2 Patient characteristics of the initial and final pooled trial cohort and the validation sets
Characteristic
Initial pooled trial cohort* Final trial cohort* Validation Maastro Validation Enschede
N (%) n (%) n (%) n (%)
Total 1240 1240 244 291
Age (y)
Median 68.0 68.0 65.8 68.0
Range 35.2-92.2 35.2-92.2 19.5-86.8 44.0-92.0
FIGO histological grade
1 344 (27.7) 730 (58.9) 93 (38.1) 96 (33.0)
2 689 (55.6) 256 (20.6) 124 (50.8) 98 (33.7)
3 207 (16.7) 254 (20.5) 20 (8.2) 91 (31.3)
Unknown 0 (0) 0 (0) 7 (2.9) 6 (2.1)
Myometrial invasion
<50% 352 (28.4) 368 (29.7) 110 (45.1) 77 (26.5)
>50% 888 (71.6) 872 (70.3) 131 (53.7) 214 (73.5)
Unknown 0 (0) 0 (0) 3 (1.2) 0 (0)
Invasion of cornuae
No 865 (69.8) 886 (71.5) 176 (72.1) 291 (100)
Yes 333 (26.9) 324 (26.1) 41 (16.8) 0 (0)
Unknown 42 (3.4) 30 (2.4) 27 (11.1) 0 (0)
Vascular invasion
No 1046 (84.4) 1106 (89.2) 192 (78.7) 246 (84.5)
Yes 111 (9.0) 117 (9.4) 52 (21.3) 45 (15.5)
Unknown 83 (6.7) 17 (1.4) 0 (0) 0 (0)
Radiation therapy
None 378 (30.5) 378 (30.5) 0 (0) 0 (0)
EBRT 648 (52.3) 648 (52.3) 150 (61.5) 203 (69.8)
VBT 214 (17.3) 214 (17.3) 94 (38.5) 88 (30.2)
Abbreviations: EBRT Z pelvic external beam radiation therapy; FIGO Z International Federation of Gynecology and Obstetrics; VBT Z vaginal
brachytherapy.
* Initial refers to the pooled trial cohort with original pathology data; the final trial cohort, which was used for analysis, included revised pathology
data (available for 86% of the patients) and substituted original pathology data for the 14% for whom no pathology review was available.
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hazard model, and model performances using the censored
outcome data were assessed by the c-index. This index has
properties similar to area under the receiver operating
characteristic curve (0.5, random prediction; 1, perfect
prediction). The variable “given treatment,” was replaced
by 2 dummy variables for EBRT and VBT because the
specific order of the values does not have a meaning (ie, the
variable is not ordinal). Age was treated as a continuous
variable and FIGO grade as an ordinal variable, and the
other invasion-related variables were converted to binary
variables (no, yes), which meant they were nominal in the
analysis.
Identifying the predictors, that is, the variables that have
a significant association with outcome, was done in a
multivariate setting, using a backward elimination process.
In this method, one starts with all variables in the multi-
variate model and tests for significance. In each subsequent
iteration, the least significant variable was excluded, and
the new combination of variables was tested again. This
process was repeated until all variables were predictive
(a Z .05). This final predictor set was used to develop the
nomograms, which are visual representations of the trained
Cox models. Performance of the nomograms wascalculated by using bootstrapping in which the evaluated
data set was tested 1000 times, and each time, data were
randomly resampled (patients could occur in the data set
more than once), and c-index was calculated. The final step
was to compute the average bootstrapped performance and
its 95% confidence interval. Calibration, that is, predicted
event rates versus observed event rates, was assessed by
plotting these quantities in subgroups with equal numbers
of patients (training: 9; subgroups, merged validation: 6
subgroups). The Hosmer-Lemeshow statistic was used to
test significance of the calibration (in this test, significant P
values relate to poor calibration).Results
Patient outcomes
Among the total of 1240 patients in our analysis, 648
(52.3%) had received adjuvant pelvic EBRT, 214 (17.3%)
had received VBT, and 378 (30.4%) had been observed
after surgery. Further treatment information and trial ori-
gins are reported in Table 1. Patient characteristics of the
pooled trial cohorts and validation sets are shown in
Creutzberg et al. International Journal of Radiation Oncology  Biology  Physics534Table 2. Rates of vaginal and pelvic recurrence, distant
metastases, and OS and DFS are shown in Table 3.
Nomogram development
For the development of the nomograms, the complete
pooled dataset with the PORTEC patients and the PORTEC
registration group with grade 3 and deep myometrial in-
vasion was used (NZ1240 patients). These data were
updated for the pathology review (Table 2). The backwards
elimination method for predictor selection resulted in
multiple predictors for the 4 assessed outcomes: LRR, DR,
DFS, and OS (Table 4). The predictors age, FIGO grade,
and LVSI were consistently selected for all outcomes. Age
(in years) had the highest hazard ratios (HR) for DFS (HR
Z 1.77) and OS (HR Z 1.94) compared to the other pre-
dictors, and FIGO grade had the highest HR for LRR (HR
Z 1.64) and DR (HR Z 1.96). Myometrial invasion was
selected for LRR, DR, and DFS but was not associated with
OS. Invasion of cornuae was not selected and was therefore
left out of the nomogram. LVSI was selected for all out-
comes (HR Z 1.1-1.2). All demographic and clinical pre-
dictors had HR of >1, meaning that higher age, higher
grade, and myometrial invasion or increase in invasion
depth are associated with a worse prognosis.
Treatment variables were associated with LRR and DFS
(HR < 1: both treatments improved these outcomes) but not
with DR and OS. This implies that pelvic EBRT and VBT
reduce LRR but do not result in improved OS, which is





VR 59 72.4 (66.5-79.4)
PR 34 74.9 (69.8-82.4)
LRR 92 74.8 (69.1-82.4)
DR 114 81.2 (73.8-92.4)
DFS 428 120 (113-126)
OS 393 139 (135-143)
Maastro (nZ244 patients)
VR 18 59.9 (55-62.4)
PR 4 57.7 (52.4-61.2)
LRR 21 59.9 (55-62.3)
DR 17 59.9 (55.4-62.4)
DFS 121 102 (82.1-121)
OS 113 213 (173-247)
Enschede (nZ291 patients)
VR 8 66.2 (55.6-77.4)
PR 15 68.2 (56-78.4)
LRR 19 69.1 (56.9-80)
DR 40 73 (66.4-87)
DFS 90 92.3 (77.9-116)
OS 81 90.4 (77.9-116)
Abbreviations: DFS Z disease-free survival; DR Z distant relapse; LRR Z
vaginal relapse.88.3% for DR-free patients versus 18.2% for patients with
DR. For LRR and DFS, the RT variables were selected,
which suggests that for those outcomes, the observational
patient group is an important reference group when
reporting the association of RT modalities with outcome.
The resulting nomograms (Fig. 1) are able to estimate
outcome probabilities for each specific outcome by
assigning a score (Fig. 1, upper scale “Score”) to each
predictor value. The sum of these scores corresponds to an
event probability.
Nomogram validation
Performances of the nomograms are reported in Table 4 for
both the training set (NZ1240) and the 2 validation sets
(nZ244 and 291). Highest training c-indices were reported
for LRR (0.78; 95% confidence interval [CI]: 0.73-0.83)
and DR (0.76; 95% CI: 0.71-0.81). The performance for
DR was reproduced in the validation datasets, with
c-indices of 0.64 and 0.76, and 0.73 for the merged set.
However, lower c-indices of 0.58 (0.44-0.71) and 0.62
(0.49-0.75) were found for LRR. The survival-related no-
mograms validated with significant consistency; for DFS,
the c-index was 0.71 (95% CI: 0.67-0.74) for training and
0.69 (95% CI: 0.63-0.75) for validation. For OS, the
c-index was 0.71 (95% CI: 0.67-0.75) for training, and this
validated very well with c-index of 0.70 (95% CI: 0.64-
0.76).
Figure 2 shows that the nomograms have a good cali-
bration when tested in both the training and the validationtraining and validation datasets
Outcome % at 5 y
(95% CI)
Outcome % at 10 y
(95% CI)
4.43 (3.16-5.68) 5.63 (4.05-7.19)
2.38 (1.42-3.33) 2.95 (1.8-4.09)
6.69 (5.13-8.22) 8.44 (6.52-10.3)
7.17 (5.58-8.73) 8.55 (6.71-10.4)
79.8 (77.3-82.3) 67 (63.8-70.3)
83.7 (81.4-86) 70.9 (67.8-74)
7.81 (3.98-11.5) 10.8 (5.15-16.2)
1.84 (0.035-3.61) 1.84 (0.035-3.61)
9.16 (5.06-13.1) 12.2 (6.33-17.7)
7.15 (3.39-10.8) 11.2 (4.39-17.4)
77.9 (72.6-83.5) 60.3 (53.1-68.5)
82.2 (77.3-87.3) 70 (63.9-76.6)
2.95 (0.91-4.95) 2.95 (0.91-4.95)
5.58 (2.65-8.42) 6.41 (3.07-9.64)
6.94 (3.75-10) 7.76 (4.2-11.2)
13.2 (8.94-17.3) 16 (11-20.7)
75.9 (70.7-81.5) 63.9 (57.4-71.2)
79.1 (74-84.5) 65.7 (59-73)
locoregional relapse; OS Z overall survival; PR Z pelvic relapse; VR Z
Table 4 HR and corresponding P values based on multivariate Cox models for selected prognostic factors with respect to the different
endpoints*
Factor
LRR DR DFS OS
HR P HR P HR P HR P
Age 1.35 .006 1.35 .001 1.77 <.001 1.94 <.001
FIGO grade 1.64 <.001 1.96 <.001 1.25 <.001 1.29 <.001
Myometrial invasion 1.50 .001 1.26 .033 1.11 .045 - -
Invasion of cornuae - - - - - - - -
Vascular invasion 1.21 .029 1.21 .007 1.13 .007 1.12 .016
EBRT 0.45 <.001 - - 0.90 .040 - -
VBT 0.64 <.001 - - 0.82 .009 - -
Training c-index (95% CI) 0.78 (0.73-0.83) 0.76 (0.71-0.81) 0.71 (0.67-0.74) 0.71 (0.67-0.75)
Validation Maastro c-index (95% CI) 0.58 (0.44-0.71) 0.64 (0.49-0.78) 0.69 (0.61-0.77) 0.71 (0.62-0.78)
Validation Enschede c-index (95% CI) 0.62 (0.49-0.75) 0.76 (0.68-0.84) 0.70 (0.62-0.78) 0.70 (0.63-0.77)
Validation merged c-index (95% CI) 0.59 (0.50-0.68) 0.73 (0.65-0.80) 0.69 (0.63-0.75) 0.70 (0.64-0.76)
Abbreviations: DFSZ disease-free survival; DRZ distant relapse; EBRTZ pelvic external beam radiation therapy; FIGOZ International Federation
of Gynecology and Obstetrics; HR Z hazard ratio; LRR Z locoregional relapse; OS Z overall survival; VBT Z vaginal brachytherapy.
* For every model the c-index with 95% confidence interval is computed for both the training dataset and the validation datasets and also for the
merged validation set.
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underestimated for the lower risk patients (P<.0001).
Application of the DFS and OS nomograms to the training
and validation datasets, respectively, are shown in
supplementary Figure E3 (available online at www.
redjournal.com). The median risk probability was used as
a threshold to distinguish between high- and low-risk pa-
tients. For both outcomes and both datasets, the Kaplan-
Meier curves were significantly distinct. This confirms the
fact that the nomograms validate well and that they have
the potency to distinguish among risk groups based on a
multivariate set of predictors.
Use of the nomograms in clinical practice
Examples of the potential use of the nomograms during
patient counseling have been described in supplementary
Table E5 (available online at www.redjournal.com). This
shows that the nomograms are especially valid for use when
counseling patients with intermediate- and high-
intermediate-risk stage I endometrial carcinoma (the risk
groups on which the nomograms have been built). For
patients with all high-risk factors (advanced age, grade 3,
LVSI, deep invasion), the model may slightly overestimate
events.
Discussion
This pooled analysis of outcome data of 1240 EC patients
treated in the randomized PORTEC-1 and PORTEC-2 trials
was done to construct nomograms which could be used to
predict long-term outcome after surgery with or without
pelvic EBRT or VBT. Because of the random treatment
allocation, the complete follow-up information, and the
large number of patients, the pooled trial databasesprovided unique data with which to reliably analyze such
outcomes. The nomograms are able to accurately predict
long-term outcome in terms of LRR, DR, and survival with
or without adjuvant treatment and have been externally
validated for survival.
All of the previously developed nomograms were able to
predict the likelihood of relapse and survival based on
prognostic factors. For example, the Australian nomogram
application is used in clinical practice for discussing indi-
vidual patients’ risks of disease recurrence based on
clinical-pathological prognostic factors (12). Likewise, the
Mayo Clinic nomogram is used to counsel a patient on the
risks and benefits of second staging surgery based on the
patient’s individual risk of having microscopic pelvic
lymph node metastases (13).
The nomograms provided in this study are unique in that
they are the first set of nomograms that include information
for outcomes with or without adjuvant EBRT or VBT. With
this inclusion of adjuvant treatment, these nomograms are
the ideal basis for individual patient information and
counseling. Both can be used after endometrial tissue
sampling and/or after definitive surgery for shared decision
making in daily clinical practice.
Decisions about the minimal benefit required to justify
adjuvant therapy as made by local or national guideline
committees do not allow for such individual preferences
and informed decisions. In view of the absence of a survival
benefit, RT for early stage EC (with or without risk factors)
was uniformly abandoned in Denmark (17). Recent results
of a Danish cancer registry study show that without adju-
vant pelvic EBRT or brachytherapy, 22% of EC patients
with intermediate risk factors will experience a relapse, and
14% of the 22% will have a locoregional recurrence (18).
PORTEC-2 data suggest that the majority of these re-
currences (12% of these 14%) could have been prevented
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Sum of scores
Distant relapse
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B
Fig. 1. Nomograms for (A) locoregional recurrence, (B) distant relapse, (C) disease-free survival, and (D) overall survival
based on the final trial cohort (with revised pathology data). EBRT and VBT should not be added (as the series did not include
patients who had both) but used separately. EBRT Z external beam radiation therapy; FIGO Z International Federation of
Gynecology and Obstetrics; G Z grade; VBT Z vaginal brachytherapy.
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be able to make their own informed choices (9). In a spe-
cific treatment preference study, EC patients reported a
relatively low minimally desired benefit of VBT (0%-8%)
at which they would prefer VBT over a watchful waiting
approach (10). The current nomogram would be an easy
and understandable instrument to be used in shared deci-
sion making, to facilitate understanding of the individual
risk profile, and to discuss whether pelvic EBRT or VBT
would be useful for the specific situation. In other cancer
types, where the decision to use adjuvant treatment is based
on risk factors, such as in breast cancer, prediction models
such as the Web-based program Adjuvant! Online have
been implemented in clinical practice worldwide (19).
Using such support systems greatly facilitates patient un-
derstanding of risks and benefits of adjuvant therapy, andhaving such models for EC would facilitate shared decision
making and also tailor the use of health care resources to
the higher risk groups. In addition, the nomograms can also
be used for selection of patients for clinical trials of adju-
vant treatments and for generation of new hypotheses.
A limitation of our study is the relatively limited number
of patients in the validation groups and the fact that the
validation groups had less performance in the validation of
LRR. Both the fact that the 2 validation sets did not include
patients with (high) intermediate risk factors who were
treated with surgery alone, and the relatively low number of
LRR events contributed to the lower c-index. However, the
performance of the validation for DR, DFS, and OS was
excellent. We aimed to avoid overfitting by reducing the
amount of predictors in the nomogram, by using the
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interpreted with caution for patients who have higher risk
factors other than the large pooled group of patients with
(high-) intermediate-risk stage I endometrial carcinoma on
which the nomograms have been built, as has been illus-
trated in supplementary Table E5 (available online at www.
redjournal.com). For patients who have all high-risk factors
(advanced age, grade 3, LVSI, deep invasion), the model
seems to somewhat overestimate recurrence rates.
The fact that many EC patients have comorbidities and
approximately 50% of deaths are due to causes other than
EC is well known. Still, it is relevant when discussing
adjuvant treatment with a patient to know how the like-
lihood of survival with and without relapse will be; in
future, such information could be added using the pa-
tient’s comorbidity profile as also used in other prediction
models such as Adjuvant! (19). Combined analysis and
validation with the Australian nomogram (13) is being
planned.A limitation of all current nomograms are that they take
into account only classic clinicopathological risk factors.
They only give a rough estimate of the patient’s expected
outcome. In our analysis, the classic risk factors increasing
age, higher FIGO grade, and presence of LVSI were
consistently selected for all outcomes, LRR, DR, DFS, and
OS. For LRR, which is the main outcome that is influenced
by pelvic EBRT and VBT in early stage EC, we found
FIGO grade to have the highest HR, and grade was of
stronger significance than LVSI and depth of myometrial
invasion. Invasion of the cornuae, where the myometrium is
thinnest and myometrial invasion is usually relatively close
to the serosa but which may not be consistently reported in
pathology reports, had the lowest impact and could be
omitted. Both this and recent analyses suggest that LVSI
may be the strongest factor for DR and survival (especially
if extensive LVSI is taken into account), and the prognostic
information of LVSI might be at least as strong as that of
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P=.562 P=.172
Fig. 2. Calibration plots show predicted event rates
versus observed event rates for equally sized subgroups of
patients. There are 9 subgroups for the training datasets and
6 for the merged validation dataset. Hosmer-Lemeshow
statistic was used to compute P values for significant
under- or overestimation of observed probabilities by the
nomograms.
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Although these nomograms are very useful in current risk
prediction and for shared decision making about adjuvant
treatment, addition of molecular genetic risk factors such as
L1 cell adhesion molecule (L1CAM) expression, POLE
proofreading mutations, TP53 mutation, microsatellite-
instability (MSI) and combinations thereof (7, 8) or of the
rhwmolecular signature (23) in risk predictionmodels might
lead to much greater precision of the risk estimates, and infuture nomograms, such features should be incorporated.
These nomograms for use in patient counseling and shared
decision making are able to accurately predict long-term
outcome in terms of locoregional recurrence, distant recur-
rence, and survival with or without adjuvant EBRT or VBT.
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